Lindbrook Capital’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Lindbrook Capital’s Portfolio GNOM Stock Details GNOM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-313	Closed	-$15.4K	–	2779
2023 Q1	$15.4K	Hold	313	–	–	﹤0.01%	1200
2022 Q4	$15.8K	Hold	313	–	–	﹤0.01%	1183
2022 Q3	$16K	Hold	313	–	–	﹤0.01%	1098
2022 Q2	$15K	Sell	313 -1,062	-77%	-$53.8K	﹤0.01%	1092
2022 Q1	$83K	Hold	1,375	–	–	0.01%	521
2021 Q4	$109K	Buy	+1,375	New	+$116K	0.02%	466

Other funds holding GNOM

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return

OCM

One Capital Management Westlake Village, California $3.65B AUM 15.32% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Lido Advisors Los Angeles, California $32.7B AUM 19.2% 1-Year Est. Return

PGA

Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

PFG

Prosperity Financial Group San Ramon, California $271M AUM 30.27% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

MWAM

Manhattan West Asset Management Los Angeles, California $511M AUM 18.81% 1-Year Est. Return

Lindbrook Capital's GNOM Position: Q2 2023 in Review

Lindbrook Capital sold out of Global X Genomics & Biotechnology ETF (GNOM) in Q2 2023, closing a stake of 313 shares — an estimated $15.4K sold.

Lindbrook Capital first reported a position in GNOM in Q4 2021 and held it in 6 quarters. The position peaked at $109K in Q4 2021. 63 funds tracked by Wall St. Rank hold GNOM as of Q2 2023.

Lindbrook Capital reported no remaining Global X Genomics & Biotechnology ETF position as of Q2 2023 after selling out during the quarter.
Lindbrook Capital sold 313 Global X Genomics & Biotechnology ETF shares in Q2 2023, an estimated $15.4K.
Lindbrook Capital first reported a position in Global X Genomics & Biotechnology ETF in Q4 2021 and held it in 6 quarters.
Lindbrook Capital's Global X Genomics & Biotechnology ETF position peaked at $109K in Q4 2021.
63 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q2 2023.

Based on Lindbrook Capital's 13F filing for Q2 2023, filed 31 Jul 2023.